# Contact Rx KPV: KPV peptide editorial inquiries

> Contact Rx KPV with editorial questions or corrections about our cited KPV peptide research summaries. We do not sell, prescribe, or supply any compound.

Editorial questions, corrections, and source suggestions about our KPV peptide summaries.

## Editorial inquiries

Use the form below to reach Rx KPV with editorial questions about our KPV peptide summaries, to flag a correction, or to suggest a peer-reviewed source we should include. We read every message that concerns the accuracy of the science or the citations. Because we treat citation accuracy as the core of this project, corrections that point to a specific study, PMID, or DOI are especially welcome.

A note on what we cannot help with: Rx KPV is an editorial publisher, not a clinic, pharmacy, or vendor. We cannot provide medical advice, recommend a dose, evaluate a person's suitability for any compound, or help anyone obtain KPV. We do not sell, prescribe, supply, or source any substance, and we cannot connect you with anyone who does. Questions about purchasing, dosing for personal use, or treatment fall outside what this site does and will not be answered.

## What to expect

Messages about the literature — a study we missed, a number that looks wrong, a citation that does not resolve — help us keep the digest accurate, and we prioritize them. For the regulatory picture, the [KPV legal status](/legal-status) page already states what FDA's own pages establish about 503A compounding and the scheduled 2026 PCAC evaluation, in the present tense and without speculation, so most access questions are answered there. This page is for editorial correspondence about the published science, nothing more.

---

A regulatory-grade reading of the KPV tripeptide record — each finding marked confirmed, preclinical, or no-human-data and cited to source, and the FDA 503A standing read straight from FDA's own pages; no clinic behind the dossier and nothing here prescribed, dispensed, or sold.